Ross Bray

2.5k total citations · 5 hit papers
21 papers, 1.9k citations indexed

About

Ross Bray is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Epidemiology. According to data from OpenAlex, Ross Bray has authored 21 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Molecular Biology and 6 papers in Epidemiology. Recurrent topics in Ross Bray's work include Diabetes Treatment and Management (12 papers), Metabolism, Diabetes, and Cancer (8 papers) and Liver Disease Diagnosis and Treatment (6 papers). Ross Bray is often cited by papers focused on Diabetes Treatment and Management (12 papers), Metabolism, Diabetes, and Cancer (8 papers) and Liver Disease Diagnosis and Treatment (6 papers). Ross Bray collaborates with scholars based in United States, Germany and Spain. Ross Bray's co-authors include Ángel Rodríguez, Laura Fernández Landó, Axel Haupt, Deborah A. Robins, Juan P. Frías, Hiren Patel, Ruth Huh, Kenneth Cusi, Amalia Gastaldelli and Dominik Dahl and has published in prestigious journals such as The Lancet, JAMA and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Ross Bray

21 papers receiving 1.9k citations

Hit Papers

Once-weekly tirzepatide versus once-daily insulin deglude... 2020 2026 2022 2024 2021 2022 2022 2020 2025 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
    2021 411 citations Bernhard Ludvik, Francesco Giorgino et al. The Lancet profile →
  2. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
    2022 387 citations Dominik Dahl, Yukiko Onishi et al. JAMA profile →
  3. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
    2022 328 citations Amalia Gastaldelli, Kenneth Cusi et al. The Lancet Diabetes & Endocrinology profile →
  4. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
    2020 271 citations Mark L. Hartman, Arun J. Sanyal et al. Diabetes Care profile →
  5. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial
    2025 23 citations Naveed Sattar, Ian J. Neeland et al. The Lancet Diabetes & Endocrinology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ross Bray United States 11 1.5k 668 526 473 446 21 1.9k
Ángel Rodríguez United States 15 1.2k 0.8× 458 0.7× 429 0.8× 372 0.8× 304 0.7× 41 1.6k
Laura Fernández Landó United States 18 2.6k 1.7× 1.1k 1.7× 990 1.9× 763 1.6× 754 1.7× 52 3.2k
Jonatan I. Bagger Denmark 23 1.4k 0.9× 623 0.9× 172 0.3× 315 0.7× 900 2.0× 58 1.9k
Hiren Patel United States 15 795 0.5× 451 0.7× 259 0.5× 204 0.4× 251 0.6× 58 1.2k
Leonard C. Glass United States 18 1.7k 1.1× 1.8k 2.7× 294 0.6× 763 1.6× 599 1.3× 32 3.3k
David P. Sonne Denmark 21 783 0.5× 502 0.8× 141 0.3× 277 0.6× 604 1.4× 53 1.6k
Bram Brouwers United States 17 655 0.4× 328 0.5× 173 0.3× 711 1.5× 195 0.4× 26 1.5k
Gianluca Bardini Italy 20 1.1k 0.7× 491 0.7× 112 0.2× 237 0.5× 432 1.0× 40 1.6k
Leonardina Ciccarelli Italy 27 1.3k 0.8× 751 1.1× 377 0.7× 289 0.6× 450 1.0× 45 2.0k
Elsie Allen United States 13 1.7k 1.1× 641 1.0× 150 0.3× 199 0.4× 682 1.5× 20 2.1k

Countries citing papers authored by Ross Bray

Since Specialization
Citations

This map shows the geographic impact of Ross Bray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ross Bray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ross Bray more than expected).

Fields of papers citing papers by Ross Bray

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ross Bray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ross Bray. The network helps show where Ross Bray may publish in the future.

Co-authorship network of co-authors of Ross Bray

This figure shows the co-authorship network connecting the top 25 collaborators of Ross Bray. A scholar is included among the top collaborators of Ross Bray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ross Bray. Ross Bray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sattar, Naveed, Ian J. Neeland, Laura Fernández Landó, et al.. (2025). Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. The Lancet Diabetes & Endocrinology. 13(6). 482–493. 23 indexed citations breakdown →
2.
Cariou, Bertrand, Jennifer Linge, Ian J. Neeland, et al.. (2024). Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes. Diabetes Obesity and Metabolism. 26(6). 2446–2455. 18 indexed citations
3.
Boye, Kristina S., Vivian T. Thieu, Hélène Sapin, et al.. (2023). Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme. Diabetes Therapy. 14(11). 1833–1852. 10 indexed citations
4.
Gastaldelli, Amalia, Kenneth Cusi, Laura Fernández Landó, et al.. (2023). Effect of Tirzepatide Versus Insulin Degludec on Liver Fat Content and Abdominal Adipose Tissue in Patients with Type 2 Diabetes (SURPASS-3 MRI). Diabetologie und Stoffwechsel. 18(S 01). S15–S16. 1 indexed citations
5.
Patel, Hiren, Kamlesh Khunti, Helena W. Rodbard, et al.. (2023). Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes Obesity and Metabolism. 26(2). 473–481. 18 indexed citations
6.
Ludvik, Bernhard, Francesco Giorgino, Esteban Jódar, et al.. (2022). EFFICACY AND SAFETY OF TIRZEPATIDE, A DUAL GIP/GLP-1 RECEPTOR AGONIST, COMPARED TO INSULIN DEGLUDEC IN PATIENTS WITH TYPE 2 DIABETES (SURPASS-3). Diabetologie und Stoffwechsel. 17(S 01). S30–S30. 1 indexed citations
7.
Bray, Ross, A. Hartley, Deborah Wenkert, et al.. (2022). Why are There not More Bayesian Clinical Trials? Ability to Interpret Bayesian and Conventional Statistics Among Medical Researchers. Therapeutic Innovation & Regulatory Science. 57(3). 426–435. 3 indexed citations
8.
Gastaldelli, Amalia, Kenneth Cusi, Laura Fernández Landó, et al.. (2022). Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. The Lancet Diabetes & Endocrinology. 10(6). 393–406. 328 indexed citations breakdown →
9.
Natanegara, Fanni, A. Hartley, Deborah Wenkert, et al.. (2022). Why are not There More Bayesian Clinical Trials? Perceived Barriers and Educational Preferences Among Medical Researchers Involved in Drug Development. Therapeutic Innovation & Regulatory Science. 57(3). 417–425. 15 indexed citations
10.
Yu, Melvin J., et al.. (2022). IDF21-0036 Patient-Reported Outcomes in Patients with Type 2 Diabetes Treated with Tirzepatide or Insulin Degludec (SURPASS-3). Diabetes Research and Clinical Practice. 186. 109700–109700. 1 indexed citations
11.
Dahl, Dominik, Yukiko Onishi, Paul Norwood, et al.. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. JAMA. 327(6). 534–534. 387 indexed citations breakdown →
12.
Ludvik, Bernhard, Francesco Giorgino, Esteban Jódar, et al.. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet. 398(10300). 583–598. 411 indexed citations breakdown →
13.
Ludvik, Bernhard, Francesco Giorgino, Esteban Jódar, et al.. (2021). 78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3). Diabetes. 70(Supplement_1). 5 indexed citations
14.
Thomas, Melissa K., et al.. (2021). 106-OR: A First-in-Human Single Ascending Dose Study of Oxyntomodulin Analog LY3305677 in Healthy Subjects. Diabetes. 70(Supplement_1). 1 indexed citations
15.
16.
Thomas, Melissa K., Amir Nikooienejad, Ross Bray, et al.. (2020). Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 106(2). 388–396. 220 indexed citations
17.
Hartman, Mark L., Arun J. Sanyal, Rohit Loomba, et al.. (2020). Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Diabetes Care. 43(6). 1352–1355. 271 indexed citations breakdown →
18.
Thomas, Melissa K., Amir Nikooienejad, Ross Bray, et al.. (2019). 980-P: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients. Diabetes. 68(Supplement_1). 5 indexed citations
19.
Hartman, Mark L., Arun J. Sanyal, Rohit Loomba, et al.. (2019). 134-OR: Effects of Tirzepatide (TZP), a Novel Dual GIP and GLP-1 Receptor Agonist, on Biomarkers of Nonalcoholic Steatohepatitis (NASH) in Patients with T2D. Diabetes. 68(Supplement_1). 4 indexed citations
20.
Loughhead, R. E. & Ross Bray. (1966). Statistics of Solar Seeing. 63. 101. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ángel Rodríguez Breakdown of academic impact, for papers by Laura Fernández Landó Breakdown of academic impact, for papers by Jonatan I. Bagger Breakdown of academic impact, for papers by Hiren Patel Breakdown of academic impact, for papers by Leonard C. Glass Breakdown of academic impact, for papers by David P. Sonne Breakdown of academic impact, for papers by Bram Brouwers Breakdown of academic impact, for papers by Gianluca Bardini Breakdown of academic impact, for papers by Leonardina Ciccarelli Breakdown of academic impact, for papers by Elsie Allen
Rankless by CCL
2026